Gliatech Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gliatech Inc.
Market Insight - Cost of capital in royalty monetisation transactions
In the current climate it is unsurprising that biopharmaceutical companies are tapping alternative sources of financing, including royalty monetisation for commercial products. Dr Ken Macleod, John Leone and Dr Walter Flamenbaum explain how investors weigh up risk when valuing such transactions.
Genzyme Bets Big on Biosurgery
Genzyme Corp is merging two of its subsidiaries, Genzyme Tissue Repair and Genzyme Surgical with a third company, Biomatrix Inc. in a bold bet on the promise of biosurgery--the combination of biomaterials and gene and cellular therapies with more traditional surgical instruments. Clinically, biosurgery will hopefully improve patient outcomes; commercially, it will differentiate surgical instrument makers whose products seem increasingly alike.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Biomaterials
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice